"Candel Therapeutics will showcase outcomes from Phase 3 trials of drug CAN-2409 for localized prostate cancer at the ASTRO 2025 conference"
Candel Therapeutics' CAN-2409 Accepted for Oral Presentation at ASTRO 2025
Candel Therapeutics, a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies for cancer, has announced that its phase 3 clinical trial of CAN-2409, a treatment for intermediate-to-high-risk localized prostate cancer, has been accepted for an oral presentation at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting.
The oral presentation, titled "SS 03 - GU 1: Advances in Localized Prostate Cancer," will take place on September 28, 2025, from 2:30 PM to 2:40 PM PT, in Room 24 at the Moscone Center, San Francisco, CA. The abstract has also been selected for inclusion in ASTRO's Science Highlights - Genitourinary Cancer session on September 28 at 8:00 a.m. PT in Room 24.
CAN-2409 is the lead product candidate from Candel's adenovirus platform. The company recently completed a pivotal, placebo-controlled, phase 3 clinical trial of CAN-2409 in localized prostate cancer. The FDA granted Regenerative Medicine Advanced Therapy Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease.
Candel's enLIGHTENTM Discovery Platform, which is used to create new viral immunotherapies for solid tumors, leverages human biology and advanced analytics. The platform has shown promising results in phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).
The company's phase 3 clinical trial of CAN-2409 has also received Fast Track Designation and Orphan Drug Designation from the FDA. The enLIGHTENTM Discovery Platform has the potential to revolutionize the treatment of various types of cancer, including localized prostate cancer.
While the presenter for the oral presentation has not been announced yet, ASTRO typically releases the complete agenda with titles, authors, and presenters a few weeks before the congress. Candel Therapeutics or the study leaders will likely announce the presentation as a "Late Breaking Abstract" or scheduled presentation once the scientific program of ASTRO is published.
Stay tuned for more updates on this exciting development in the world of cancer research and treatment. For the latest news and updates, visit the official ASTRO website, Candel Therapeutics' website, or medical news portals like Medscape, Healio, or Onclive. You can also send a direct inquiry to Candel Therapeutics or ASTRO's press office.
Background
ASTRO usually publishes the complete agenda with titles, authors, and presenters only a few weeks before the congress. Candel Therapeutics or the study leaders will typically announce such presentations as "Late Breaking Abstract" or scheduled presentations once the scientific program of ASTRO is published. Phase 3 studies of important cancer drugs are often presented by leading study doctors (Principal Investigators, PIs) or heads of clinical research at the respective companies.
How to Stay Informed
- ASTRO-Website: Keep an eye on the official ASTRO-Website. The scientific program, including presenters, will be published there.
- Candel Therapeutics: The company will announce the presentation on its website or in press releases.
- Medical News Portals: Websites like Medscape, Healio, or Onclive often report on major study presentations well in advance.
- Direct Inquiry: You can also send a brief inquiry to Candel Therapeutics' or ASTRO's press office.
Note
Since this event is scheduled for 2025, the details are not yet reliably available. The abstracts will be accepted and the congress program will be published at the earliest in the summer of 2025. Please check back in the spring of 2025 for the latest updates! I'll be happy to help you research and compile the current details then.
